Trial Outcomes & Findings for Evaluation of the Safety and Effectiveness of ALLEVYN Gentle Border (NCT NCT03877484)

NCT ID: NCT03877484

Last Updated: 2024-12-09

Results Overview

Change in wound area from baseline to end of study visit at 28 days was measured by wound photographs from a specific digital camera that standardized and calculated wound length, width, and depth automatically.

Recruitment status

COMPLETED

Target enrollment

43 participants

Primary outcome timeframe

Baseline through 28 days (±3 days).

Results posted on

2024-12-09

Participant Flow

Three participants were terminated prior to study treatment, following consent, and did not meet eligibility criteria.

Participant milestones

Participant milestones
Measure
ALLEVYN Gentle Border
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Overall Study
STARTED
40
Overall Study
COMPLETED
30
Overall Study
NOT COMPLETED
10

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Evaluation of the Safety and Effectiveness of ALLEVYN Gentle Border

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
ALLEVYN Gentle Border
n=40 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Age, Continuous
69.6 years
STANDARD_DEVIATION 18.6 • n=39 Participants
Sex: Female, Male
Female
18 Participants
n=39 Participants
Sex: Female, Male
Male
22 Participants
n=39 Participants
Race/Ethnicity, Customized
Race/Ethnicity · Caucasian
38 Participants
n=39 Participants
Race/Ethnicity, Customized
Race/Ethnicity · Missing
2 Participants
n=39 Participants
Body Mass Index (BMI)
28.1 kg/m^2
STANDARD_DEVIATION 6.1 • n=39 Participants
Wound Type
Acute
14 Participants
n=39 Participants
Wound Type
Chronic
26 Participants
n=39 Participants
Wound Duration
158.3 days
STANDARD_DEVIATION 266.4 • n=39 Participants
Wound Area
11.9 cm^2
STANDARD_DEVIATION 13.8 • n=39 Participants
Exudate Levels
None
6 Participants
n=39 Participants
Exudate Levels
Scant
4 Participants
n=39 Participants
Exudate Levels
Small
17 Participants
n=39 Participants
Exudate Levels
Moderate
11 Participants
n=39 Participants
Exudate Levels
Large
2 Participants
n=39 Participants

PRIMARY outcome

Timeframe: Baseline through 28 days (±3 days).

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated using the last observation carried forward (LOCF).

Change in wound area from baseline to end of study visit at 28 days was measured by wound photographs from a specific digital camera that standardized and calculated wound length, width, and depth automatically.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=40 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Change in Wound Area From Baseline to End of Study Visit
2.2 square centimeters (cm^2)
Interval 0.9 to 3.9

SECONDARY outcome

Timeframe: Baseline to 7 days (±3 days), 14 days (±3 days), and 21 days (±3 days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Change in wound area from baseline to 7 days, 14 days and 21 days. Wound area was measured by photographs from a specific digital camera that standardized and calculated wound length, width, and depth automatically.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=37 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Change in Wound Area From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), and 21 Days (±3 Days)
Baseline to 7 days (±3 days)
0.5 square centimeters (cm^2)
Interval -0.2 to 0.8
Change in Wound Area From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), and 21 Days (±3 Days)
Baseline to 14 days (±3 days)
1.2 square centimeters (cm^2)
Interval 0.5 to 2.1
Change in Wound Area From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), and 21 Days (±3 Days)
Baseline to 21 days (±3 days)
1.7 square centimeters (cm^2)
Interval 0.6 to 3.1

SECONDARY outcome

Timeframe: Baseline, 7 days, 14 days, 21 days, 28 days

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Wound depth at baseline, 7, 14, 21 and 28 days were measured by wound photographs from a specific digital camera that standardized and calculated wound length, width, and depth automatically.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=34 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Change in Wound Depth From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Baseline to 14 Days
0.1 millimeters (mm)
Interval -0.01 to 0.3
Change in Wound Depth From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Baseline to 21 Days
0.1 millimeters (mm)
Interval -0.01 to 0.6
Change in Wound Depth From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Baseline to 28 Days
0.1 millimeters (mm)
Interval -0.01 to 0.6
Change in Wound Depth From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Baseline to 7 Days
0.1 millimeters (mm)
Interval 0.01 to 0.3

SECONDARY outcome

Timeframe: Baseline, 7 days, 14 days, 21 days, and 28 days

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Change in exudate wound volume measured from baseline to 7 days, 14 days, 21 days and 28 days.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=34 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Change in Wound Volume From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Baseline to 7 Days (±3 Days)
0.07 cubic centimeter (cm^3)
Interval -0.01 to 0.2
Change in Wound Volume From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Baseline to 14 Days (±3 Days)
0.08 cubic centimeter (cm^3)
Interval -0.01 to 0.2
Change in Wound Volume From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Baseline to 21 Days (±3 Days)
0.1 cubic centimeter (cm^3)
Interval 0.01 to 0.3
Change in Wound Volume From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Baseline to 28 Days (±3 Days)
0.1 cubic centimeter (cm^3)
Interval 0.02 to 0.3

SECONDARY outcome

Timeframe: Baseline to 7 days (±3 days), 14 days (±3 days), and 21 days (±3 days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Percentage change in wound area from baseline visit to visits 2 (7 Days), 3 (14 days) and 4 (21 days).

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=37 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Percentage Change in Wound Area From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), and 21 Days (±3 Days)
Baseline to 7 days (±3 days)
9.5 percent change in wound area
Interval -37.9 to 91.8
Percentage Change in Wound Area From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), and 21 Days (±3 Days)
Baseline to 14 days (±3 days)
21.3 percent change in wound area
Interval -118.8 to 100.0
Percentage Change in Wound Area From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), and 21 Days (±3 Days)
Baseline to 21 days (±3 days)
40.8 percent change in wound area
Interval -152.8 to 100.0
Percentage Change in Wound Area From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), and 21 Days (±3 Days)
Baseline to 28 Days
49.9 percent change in wound area
Interval -114.0 to 100.0

SECONDARY outcome

Timeframe: Baseline to 7 days (±3 days), 14 days (±3 days), and 21 days (±3 days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Percentage change in wound depth from baseline visit to visits 2 (7 Days), 3 (14 days) and 4 (21 days).

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=34 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Percentage Change in Wound Depth From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), and 21 Days (±3 Days)
Baseline to 7 days (±3 days)
29.1 percent change in wound depth
Interval -4402.2 to 94.6
Percentage Change in Wound Depth From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), and 21 Days (±3 Days)
Baseline to 14 days (±3 days)
34.7 percent change in wound depth
Interval -1306.0 to 100.0
Percentage Change in Wound Depth From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), and 21 Days (±3 Days)
Baseline to 21 days (±3 days)
40 percent change in wound depth
Interval -3795.5 to 100.0
Percentage Change in Wound Depth From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), and 21 Days (±3 Days)
Baseline to 28 Days (±3 days)
27.7 percent change in wound depth
Interval -1433.9 to 100.0

SECONDARY outcome

Timeframe: Baseline to 7 days (±3 days), 14 days (±3 days), and 21 days (±3 days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Percentage change in wound volume from baseline visit to visits 2 (7 Days), 3 (14 days) and 4 (21 days).

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=34 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Percentage Change in Wound Volume From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), and 21 Days (±3 Days)
Baseline to 7 days (±3 days)
38.7 percent change in wound volume
Interval -5023.5 to 97.6
Percentage Change in Wound Volume From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), and 21 Days (±3 Days)
Baseline to 14 days (±3 days)
21.3 percent change in wound volume
Interval -118.8 to 100.0
Percentage Change in Wound Volume From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), and 21 Days (±3 Days)
Baseline to 21 days (±3 days)
40.8 percent change in wound volume
Interval -152.8 to 100.0
Percentage Change in Wound Volume From Baseline to 7 Days (±3 Days), 14 Days (±3 Days), and 21 Days (±3 Days)
Baseline to 28 Days (±3 days)
49.9 percent change in wound volume
Interval -114.0 to 100.0

SECONDARY outcome

Timeframe: Dressing application to removal, up to 7 days (±3 Days)

Population: Only participants enrolled in the study with any Exudate Levels present (i.e., scant, small, moderate, or large) that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated. Of the 40 participants enrolled, 34 participants had exudate present.

The count of dressings applied on participants with exudate present that experienced any dressing leakage (Yes/No).

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=242 dressings
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Exudate Management: Number of Dressings With Leakage
Any Dressing Leakage: Yes
34 dressings
Exudate Management: Number of Dressings With Leakage
Any Dressing Leakage: No
208 dressings

SECONDARY outcome

Timeframe: 7 days (±3 Days), 14 days (±3 Days), 21 days (±3 Days), and 28 days (±3 Days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Count of participants with wound exudate amounts identified as: * None * Scant * Small * Moderate * Large

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=40 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
7 days (±3 Days) · None
5 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
7 days (±3 Days) · Scant
4 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
7 days (±3 Days) · Small
13 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
7 days (±3 Days) · Moderate
16 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
7 days (±3 Days) · Large
2 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
14 days (±3 Days) · None
7 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
14 days (±3 Days) · Scant
2 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
14 days (±3 Days) · Small
19 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
14 days (±3 Days) · Moderate
11 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
14 days (±3 Days) · Large
1 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
21 days (±3 Days) · None
7 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
21 days (±3 Days) · Scant
2 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
21 days (±3 Days) · Small
20 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
21 days (±3 Days) · Moderate
9 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
21 days (±3 Days) · Large
2 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
28 days (±3 Days) · None
8 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
28 days (±3 Days) · Scant
3 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
28 days (±3 Days) · Small
17 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
28 days (±3 Days) · Moderate
8 Participants
Exudate Amount at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
28 days (±3 Days) · Large
4 Participants

SECONDARY outcome

Timeframe: 7 days (±3 Days), 14 days (±3 Days), 21 days (±3 Days), and 28 days (±3 Days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Count of participants with wound exudate types identified as: * None * Bloody * Serosanguineous * Serous * Purulent

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=40 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
14 days (±3 Days) · None
7 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
14 days (±3 Days) · Bloody
1 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
14 days (±3 Days) · Serosanguineous
19 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
14 days (±3 Days) · Serous
7 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
14 days (±3 Days) · Purulent
6 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
21 days (±3 Days) · None
7 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
21 days (±3 Days) · Bloody
1 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
21 days (±3 Days) · Serosanguineous
21 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
21 days (±3 Days) · Serous
7 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
21 days (±3 Days) · Purulent
4 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
28 days (±3 Days) · None
8 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
28 days (±3 Days) · Bloody
0 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
28 days (±3 Days) · Serosanguineous
19 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
7 days (±3 Days) · None
5 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
7 days (±3 Days) · Bloody
1 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
7 days (±3 Days) · Serosanguineous
20 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
7 days (±3 Days) · Serous
11 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
7 days (±3 Days) · Purulent
3 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
28 days (±3 Days) · Serous
9 Participants
Exudate Type at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 Days (±3 Days)
28 days (±3 Days) · Purulent
4 Participants

SECONDARY outcome

Timeframe: Baseline, 7 days (±3 Days), 14 days (±3 Days), 21 days (±3 Days), 28 days (±3 Days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Count of participants level of odour at baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days), and 28 Days (±3 Days) identified as: * None * Mild * Moderate * Strong

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=40 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Baseline · None
34 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Baseline · Mild
5 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Baseline · Moderate
0 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Baseline · Strong
1 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
7 days (±3 Days) · None
34 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
7 days (±3 Days) · Moderate
0 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
7 days (±3 Days) · Strong
0 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
14 days (±3 Days) · None
30 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
14 days (±3 Days) · Mild
6 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
14 days (±3 Days) · Moderate
0 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
14 days (±3 Days) · Strong
0 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
21 days (±3 Days) · None
26 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
21 days (±3 Days) · Moderate
0 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
21 days (±3 Days) · Strong
0 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
28 days (±3 Days) · None
26 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
28 days (±3 Days) · Mild
4 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
28 days (±3 Days) · Moderate
0 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
28 days (±3 Days) · Strong
0 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
7 days (±3 Days) · Mild
6 Participants
Level of Wound Odour at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
21 days (±3 Days) · Mild
6 Participants

SECONDARY outcome

Timeframe: Upon dressing removal, up to 7 days (±3 Days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Overall frequency of dressing changes categorized with the following reasons(Yes/No): * Reason for dressing change routine * ALLEVYN been in place 7 days * Dressing saturated * Strikethrough * Leakage * Pain * Dressing fell off * Dressing got wet during shower/bathing * Subject removed dressing * Other

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=222 dressings
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Reason for Dressing Change
Reason for dressing change routine · No
34 dressings
Reason for Dressing Change
Reason for dressing change routine · Yes
72 dressings
Reason for Dressing Change
ALLEVYN been in place 7 days · No
195 dressings
Reason for Dressing Change
ALLEVYN been in place 7 days · Yes
27 dressings
Reason for Dressing Change
Dressing saturated · No
195 dressings
Reason for Dressing Change
Dressing saturated · Yes
27 dressings
Reason for Dressing Change
Strikethrough · No
197 dressings
Reason for Dressing Change
Strikethrough · Yes
25 dressings
Reason for Dressing Change
Leakage · No
212 dressings
Reason for Dressing Change
Leakage · Yes
10 dressings
Reason for Dressing Change
Pain · No
221 dressings
Reason for Dressing Change
Pain · Yes
1 dressings
Reason for Dressing Change
Dressing fell off · No
215 dressings
Reason for Dressing Change
Dressing fell off · Yes
7 dressings
Reason for Dressing Change
Dressing got wet during shower/bathing · No
220 dressings
Reason for Dressing Change
Dressing got wet during shower/bathing · Yes
2 dressings
Reason for Dressing Change
Subject removed dressing · No
221 dressings
Reason for Dressing Change
Subject removed dressing · Yes
1 dressings
Reason for Dressing Change
Other · No
146 dressings
Reason for Dressing Change
Other · Yes
76 dressings

SECONDARY outcome

Timeframe: Baseline and 28 days (±3 Days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

The condition of surrounding skin (i.e., peri-wound) was assessed to ensure there was no compromise to skin condition as a result of dressing wear, which could impact the wound healing progress. Number of participants condition of the peri-wound was classified as: * Normal * Erythematous * 50% to \<75% wound covered * 25% to \<50% wound covered * \<25% wound covered * Missing

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=40 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Condition of Surrounding Skin
Baseline · Normal
22 Participants
Condition of Surrounding Skin
Baseline · Erythematous
14 Participants
Condition of Surrounding Skin
Baseline · 50% to <75% wound covered
0 Participants
Condition of Surrounding Skin
Baseline · 25% to <50% wound covered
0 Participants
Condition of Surrounding Skin
28 days (±3 Days) · Normal
18 Participants
Condition of Surrounding Skin
28 days (±3 Days) · Erythematous
9 Participants
Condition of Surrounding Skin
28 days (±3 Days) · 50% to <75% wound covered
1 Participants
Condition of Surrounding Skin
28 days (±3 Days) · 25% to <50% wound covered
0 Participants
Condition of Surrounding Skin
28 days (±3 Days) · <25% wound covered
0 Participants
Condition of Surrounding Skin
28 days (±3 Days) · Missing
2 Participants
Condition of Surrounding Skin
Baseline · <25% wound covered
4 Participants
Condition of Surrounding Skin
Baseline · Missing
0 Participants

SECONDARY outcome

Timeframe: 7 days (±3 Days), 14 days (±3 Days), 21 days (±3 Days), 28 days (±3 Days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Any signs of clinical infection (Yes/No) identified at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Day (±3 Days) visits.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=39 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Signs of Clinical Infection
7 days (±3 Days) · Yes
2 Participants
Signs of Clinical Infection
7 days (±3 Days) · No
37 Participants
Signs of Clinical Infection
14 days (±3 Days) · Yes
2 Participants
Signs of Clinical Infection
14 days (±3 Days) · No
34 Participants
Signs of Clinical Infection
21 days (±3 Days) · Yes
1 Participants
Signs of Clinical Infection
21 days (±3 Days) · No
31 Participants
Signs of Clinical Infection
28 days (±3 Days) · Yes
1 Participants
Signs of Clinical Infection
28 days (±3 Days) · No
29 Participants

SECONDARY outcome

Timeframe: 7 days (±3 Days), 14 days (±3 Days), 21 days (±3 Days), 28 days (±3 Days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Wound healed (Yes/No) identified at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 day (±3 Days) visits.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=40 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Healing of Reference Wound
7 days (±3 Days) · Yes
0 Participants
Healing of Reference Wound
7 days (±3 Days) · No
40 Participants
Healing of Reference Wound
14 days (±3 Days) · Yes
1 Participants
Healing of Reference Wound
14 days (±3 Days) · No
35 Participants
Healing of Reference Wound
21 days (±3 Days) · Yes
1 Participants
Healing of Reference Wound
21 days (±3 Days) · No
31 Participants
Healing of Reference Wound
28 days (±3 Days) · Yes
1 Participants
Healing of Reference Wound
28 days (±3 Days) · No
29 Participants

SECONDARY outcome

Timeframe: Following dressing application, up to 7 days (±3 Days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Average dressing wear time in days following application

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=40 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Average Dressing Wear Time
4.3 days
Standard Deviation 1.7

SECONDARY outcome

Timeframe: Immediately after dressing application

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Level of pain was scored on a scale from 0 to 10 with 0 indicating no pain and 10 indicating the worst pain. Participants provided their level of pain upon each dressing application at each scheduled study visit (7 days, 14 days, 21 days) or at any routine dressing change visit occurring between the scheduled visits.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=252 dressings
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Overall Level of Pain on Dressing Application
1.1 score on a scale
Standard Deviation 2.0

SECONDARY outcome

Timeframe: During treatment (following each dressing application prior to removal), up to 7 days (±3 Days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Level of pain was scored on a scale from 0 to 10 with 0 indicating no pain and 10 indicating the worst pain. Participants provided their level of pain during treatment after each dressing application at each scheduled study visit (7 days \[ ±3 days\], 14 days \[ ±3 days\], 21 days \[ ±3 days\]) or at any routine dressing change visit occurring between the scheduled visits.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=245 dressings
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Overall Level of Pain During Treatment
1.9 score on a scale
Standard Deviation 2.6

SECONDARY outcome

Timeframe: Immediately upon dressing removal

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Level of pain was scored on a scale from 0 to 10 with 0 indicating no pain and 10 indicating the worst pain. Participants provided their level of pain on dressing removal for each dressing applied at each scheduled study visit (7 days \[ ±3 days\], 14 days \[ ±3 days\], 21 days \[ ±3 days\]) or at any routine dressing change visit occurring between the scheduled visits.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=246 dressings
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Overall Level Pain on Dressing Removal
1.1 score on a scale
Standard Deviation 2.1

SECONDARY outcome

Timeframe: Baseline, 7 days (±3 Days), 14 days (±3 Days), 21 days (±3 Days), and 28 days (±3 Days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

The Cardiff Wound Impact Schedule (CWIS) was collected at baseline and all study visits. Participants scored on a scale of 0 to 10 their perceived quality of life and satisfaction with quality of life. Higher scores indicate a better outcome.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=40 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Cardiff Wound Impact Schedule (CWIS): Quality of Life at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Quality of Life: Baseline
6.2 score on a scale
Standard Deviation 2.2
Cardiff Wound Impact Schedule (CWIS): Quality of Life at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Quality of Life: 7 days (±3 Days)
6.3 score on a scale
Standard Deviation 2.4
Cardiff Wound Impact Schedule (CWIS): Quality of Life at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Quality of Life: 14 days (±3 Days)
5.9 score on a scale
Standard Deviation 2.4
Cardiff Wound Impact Schedule (CWIS): Quality of Life at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Quality of Life: 28 days (±3 Days)
6.6 score on a scale
Standard Deviation 2.2
Cardiff Wound Impact Schedule (CWIS): Quality of Life at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Satisfaction with Quality of Life: Baseline
6.2 score on a scale
Standard Deviation 2.7
Cardiff Wound Impact Schedule (CWIS): Quality of Life at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Satisfaction with Quality of Life: 7 days (±3 Days)
6.0 score on a scale
Standard Deviation 3.0
Cardiff Wound Impact Schedule (CWIS): Quality of Life at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Satisfaction with Quality of Life: 14 days (±3 Days)
6.1 score on a scale
Standard Deviation 2.6
Cardiff Wound Impact Schedule (CWIS): Quality of Life at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Satisfaction with Quality of Life: 21 days (±3 Days)
6.4 score on a scale
Standard Deviation 2.6
Cardiff Wound Impact Schedule (CWIS): Quality of Life at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Satisfaction with Quality of Life: 28 days (±3 Days)
6.2 score on a scale
Standard Deviation 2.6
Cardiff Wound Impact Schedule (CWIS): Quality of Life at Baseline, 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Days (±3 Days)
Quality of Life: 21 days (±3 Days)
6.5 score on a scale
Standard Deviation 2.3

SECONDARY outcome

Timeframe: Baseline, 7 days (±3 Days), 14 days (±3 Days), 21 days (±3 Days), 28 days (±3 Days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

The Cardiff Wound Impact Schedule (CWIS) was collected at baseline and all study visits. Scores were on a scale from 0 to 100 with a higher score indicating a better outcome across three domains that included: * Wellbeing * Physical Symptoms \& Daily Living * Social Life

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=40 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Cardiff Wound Impact Schedule (CWIS): Wellbeing, Physical Symptoms & Daily Living, and Social Life at Baseline, 7 (±3 Days), 14 (±3 Days), 21 (±3 Days), and 28 Days (±3 Days)
Wellbeing: Baseline
52.6 score on a scale
Standard Deviation 22.4
Cardiff Wound Impact Schedule (CWIS): Wellbeing, Physical Symptoms & Daily Living, and Social Life at Baseline, 7 (±3 Days), 14 (±3 Days), 21 (±3 Days), and 28 Days (±3 Days)
Wellbeing: 7 days (±3 Days)
55.5 score on a scale
Standard Deviation 23.1
Cardiff Wound Impact Schedule (CWIS): Wellbeing, Physical Symptoms & Daily Living, and Social Life at Baseline, 7 (±3 Days), 14 (±3 Days), 21 (±3 Days), and 28 Days (±3 Days)
Wellbeing: 14 days (±3 Days)
60.8 score on a scale
Standard Deviation 23.2
Cardiff Wound Impact Schedule (CWIS): Wellbeing, Physical Symptoms & Daily Living, and Social Life at Baseline, 7 (±3 Days), 14 (±3 Days), 21 (±3 Days), and 28 Days (±3 Days)
Wellbeing: 21 days (±3 Days)
63.8 score on a scale
Standard Deviation 21.0
Cardiff Wound Impact Schedule (CWIS): Wellbeing, Physical Symptoms & Daily Living, and Social Life at Baseline, 7 (±3 Days), 14 (±3 Days), 21 (±3 Days), and 28 Days (±3 Days)
Wellbeing: 28 days (±3 Days)
61.4 score on a scale
Standard Deviation 39
Cardiff Wound Impact Schedule (CWIS): Wellbeing, Physical Symptoms & Daily Living, and Social Life at Baseline, 7 (±3 Days), 14 (±3 Days), 21 (±3 Days), and 28 Days (±3 Days)
Physical Symptoms & Daily Living: Baseline
69.9 score on a scale
Standard Deviation 21.0
Cardiff Wound Impact Schedule (CWIS): Wellbeing, Physical Symptoms & Daily Living, and Social Life at Baseline, 7 (±3 Days), 14 (±3 Days), 21 (±3 Days), and 28 Days (±3 Days)
Physical Symptoms & Daily Living: 7 days (±3 Days)
76.4 score on a scale
Standard Deviation 17.0
Cardiff Wound Impact Schedule (CWIS): Wellbeing, Physical Symptoms & Daily Living, and Social Life at Baseline, 7 (±3 Days), 14 (±3 Days), 21 (±3 Days), and 28 Days (±3 Days)
Physical Symptoms & Daily Living: 14 days (±3 Days)
79.2 score on a scale
Standard Deviation 17.7
Cardiff Wound Impact Schedule (CWIS): Wellbeing, Physical Symptoms & Daily Living, and Social Life at Baseline, 7 (±3 Days), 14 (±3 Days), 21 (±3 Days), and 28 Days (±3 Days)
Physical Symptoms & Daily Living: 21 days (±3 Days)
81.2 score on a scale
Standard Deviation 16.9
Cardiff Wound Impact Schedule (CWIS): Wellbeing, Physical Symptoms & Daily Living, and Social Life at Baseline, 7 (±3 Days), 14 (±3 Days), 21 (±3 Days), and 28 Days (±3 Days)
Physical Symptoms & Daily Living: 28 days (±3 Days)
81.2 score on a scale
Standard Deviation 17.4
Cardiff Wound Impact Schedule (CWIS): Wellbeing, Physical Symptoms & Daily Living, and Social Life at Baseline, 7 (±3 Days), 14 (±3 Days), 21 (±3 Days), and 28 Days (±3 Days)
Social Life: Baseline
72.4 score on a scale
Standard Deviation 20.8
Cardiff Wound Impact Schedule (CWIS): Wellbeing, Physical Symptoms & Daily Living, and Social Life at Baseline, 7 (±3 Days), 14 (±3 Days), 21 (±3 Days), and 28 Days (±3 Days)
Social Life: 7 days (±3 Days)
77.1 score on a scale
Standard Deviation 17.9
Cardiff Wound Impact Schedule (CWIS): Wellbeing, Physical Symptoms & Daily Living, and Social Life at Baseline, 7 (±3 Days), 14 (±3 Days), 21 (±3 Days), and 28 Days (±3 Days)
Social Life: 14 days (±3 Days)
82.4 score on a scale
Standard Deviation 21.1
Cardiff Wound Impact Schedule (CWIS): Wellbeing, Physical Symptoms & Daily Living, and Social Life at Baseline, 7 (±3 Days), 14 (±3 Days), 21 (±3 Days), and 28 Days (±3 Days)
Social Life: 21 days (±3 Days)
86.8 score on a scale
Standard Deviation 13.1
Cardiff Wound Impact Schedule (CWIS): Wellbeing, Physical Symptoms & Daily Living, and Social Life at Baseline, 7 (±3 Days), 14 (±3 Days), 21 (±3 Days), and 28 Days (±3 Days)
Social Life: 28 days (±3 Days)
85.3 score on a scale
Standard Deviation 13.5

SECONDARY outcome

Timeframe: 7 days (±3 Days), 14 days (±3 Days), 21 days (±3 Days), 28 days (±3 Days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

The investigator determined retention by dressing adherence to the wound at 7 Days (±3 Days), 14 Days (±3 Days), 21 Days (±3 Days) and 28 Day (±3 Days) visits. Dressing adherence reported as the number of participants for each response to the question "Dressing still fully adhered?" from one of the following options: * Yes * Yes, but with the aid of tape or other material * No, study dressing partially adhered * No, study dressing not adhered

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=38 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Dressing Adherence (Retention)
7 days (±3 Days) · Yes
20 Participants
Dressing Adherence (Retention)
7 days (±3 Days) · Yes, but with the aid of tape or other material
12 Participants
Dressing Adherence (Retention)
7 days (±3 Days) · No, study dressing partially adhered
4 Participants
Dressing Adherence (Retention)
7 days (±3 Days) · No, study dressing not adhered
2 Participants
Dressing Adherence (Retention)
21 days (±3 Days) · Yes
20 Participants
Dressing Adherence (Retention)
21 days (±3 Days) · Yes, but with the aid of tape or other material
8 Participants
Dressing Adherence (Retention)
21 days (±3 Days) · No, study dressing partially adhered
3 Participants
Dressing Adherence (Retention)
21 days (±3 Days) · No, study dressing not adhered
1 Participants
Dressing Adherence (Retention)
28 days (±3 Days) · Yes
21 Participants
Dressing Adherence (Retention)
28 days (±3 Days) · Yes, but with the aid of tape or other material
5 Participants
Dressing Adherence (Retention)
28 days (±3 Days) · No, study dressing partially adhered
1 Participants
Dressing Adherence (Retention)
28 days (±3 Days) · No, study dressing not adhered
2 Participants
Dressing Adherence (Retention)
14 days (±3 Days) · Yes
20 Participants
Dressing Adherence (Retention)
14 days (±3 Days) · Yes, but with the aid of tape or other material
14 Participants
Dressing Adherence (Retention)
14 days (±3 Days) · No, study dressing partially adhered
1 Participants
Dressing Adherence (Retention)
14 days (±3 Days) · No, study dressing not adhered
1 Participants

SECONDARY outcome

Timeframe: 7 days (±3 Days), 14 days (±3 Days), 21 days (±3 Days), 28 days (±3 Days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

The investigator determined any "bunching up" (i.e., bunching/overlap) of the dressing on the wound at 7 (±3 Days), 14 (±3 Days), 21 (±3 Days) and 28 day visits (±3 Days). Bunching of the dressing reported as the number of participants for each response to "Whether there is any bunching/overlap of dressing" from one of the following options: * None * Very Little * Moderate * Excessive

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=36 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Bunching Up of Dressing
7 days (±3 Days) · None
29 Participants
Bunching Up of Dressing
7 days (±3 Days) · Very Little
5 Participants
Bunching Up of Dressing
7 days (±3 Days) · Moderate
2 Participants
Bunching Up of Dressing
7 days (±3 Days) · Excessive
0 Participants
Bunching Up of Dressing
14 days (±3 Days) · None
33 Participants
Bunching Up of Dressing
14 days (±3 Days) · Very Little
2 Participants
Bunching Up of Dressing
14 days (±3 Days) · Moderate
0 Participants
Bunching Up of Dressing
28 days (±3 Days) · Moderate
1 Participants
Bunching Up of Dressing
28 days (±3 Days) · Excessive
0 Participants
Bunching Up of Dressing
14 days (±3 Days) · Excessive
1 Participants
Bunching Up of Dressing
21 days (±3 Days) · None
21 Participants
Bunching Up of Dressing
21 days (±3 Days) · Very Little
5 Participants
Bunching Up of Dressing
21 days (±3 Days) · Moderate
1 Participants
Bunching Up of Dressing
21 days (±3 Days) · Excessive
2 Participants
Bunching Up of Dressing
28 days (±3 Days) · None
25 Participants
Bunching Up of Dressing
28 days (±3 Days) · Very Little
1 Participants

SECONDARY outcome

Timeframe: Dressing application to removal, up to 7 days (±3 Days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Overall percentage of dressing lift for each dressing application was determined from investigator responses following dressing removal at scheduled or routine dressing change visits to the question "Is the study dressing still fully adhered?" The following imputations were used when : * If the Investigator answered "Yes" then percentage lift was 0% * If the Investigator answered "Study dressing not adhered" then the percentage lift was 100% * If "Partially adhered" was selected, then the percentage lift was the percentage indicated in data

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=250 dressings
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Overall Percent of Dressing Lift
5.8 percentage of dressing lift
Standard Deviation 20.6

SECONDARY outcome

Timeframe: 7 days (±3 Days), 14 days (±3 Days), 21 days( ±3 Days), 28 days (±3 Days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Dressing comfort at 7 days (±3 Days) , 14 days (±3 Days), 21 days (±3 Days) and 28 day (±3 Days) visits determined by the number of participants with responses to "Dressing comfortable to wear since last visit" from one of the following options: * Very comfortable * Comfortable * Neither comfortable nor uncomfortable * Uncomfortable * Very uncomfortable

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=38 Participants
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Dressing Comfort During Wear
7 days (±3 Days) · Very comfortable
20 Participants
Dressing Comfort During Wear
7 days (±3 Days) · Comfortable
15 Participants
Dressing Comfort During Wear
7 days (±3 Days) · Neither comfortable nor uncomfortable
1 Participants
Dressing Comfort During Wear
7 days (±3 Days) · Uncomfortable
1 Participants
Dressing Comfort During Wear
7 days (±3 Days) · Very uncomfortable
1 Participants
Dressing Comfort During Wear
14 days (±3 Days) · Very comfortable
19 Participants
Dressing Comfort During Wear
14 days (±3 Days) · Comfortable
15 Participants
Dressing Comfort During Wear
14 days (±3 Days) · Neither comfortable nor uncomfortable
0 Participants
Dressing Comfort During Wear
14 days (±3 Days) · Uncomfortable
1 Participants
Dressing Comfort During Wear
14 days (±3 Days) · Very uncomfortable
0 Participants
Dressing Comfort During Wear
21 days (±3 Days) · Very comfortable
16 Participants
Dressing Comfort During Wear
21 days (±3 Days) · Comfortable
13 Participants
Dressing Comfort During Wear
21 days (±3 Days) · Neither comfortable nor uncomfortable
1 Participants
Dressing Comfort During Wear
21 days (±3 Days) · Uncomfortable
1 Participants
Dressing Comfort During Wear
21 days (±3 Days) · Very uncomfortable
0 Participants
Dressing Comfort During Wear
28 days (±3 Days) · Very comfortable
17 Participants
Dressing Comfort During Wear
28 days (±3 Days) · Comfortable
12 Participants
Dressing Comfort During Wear
28 days (±3 Days) · Neither comfortable nor uncomfortable
1 Participants
Dressing Comfort During Wear
28 days (±3 Days) · Uncomfortable
0 Participants
Dressing Comfort During Wear
28 days (±3 Days) · Very uncomfortable
0 Participants

SECONDARY outcome

Timeframe: Baseline through end of treatment, up to 28 days (±3 days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Patient assessment scale completed from baseline visit through end of treatment visits, up to 28 Day (±3 days), using the participant response for each criteria to provide an overall score. Scores ranged from 0 to 10 with 0 indicating a worse outcome and 10 indicating the best outcome. Leakage was determined based on the response to "How have you found your experience in terms of leakage?" where 0 indicated unacceptable level of leakage and 10 indicated no leakage.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=244 dressings
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Patient Assessment Scale: Leakage
8.6 score on a scale
Standard Deviation 2.7

SECONDARY outcome

Timeframe: Baseline through end of treatment, up to 28 days (±3 days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Patient assessment scale completed from baseline visit through end of treatment visits, up to 28 Day (±3 days), using the participant response for each criteria to provide an overall score. Scores ranged from 0 to 10 with 0 indicating a worse outcome and 10 indicating the best outcome. Moisture was determined based on the response to "How have you found your experience in terms of the feeling of moisture on your skin underneath the dressing" where 0 indicated unacceptable feeling of moisture and 10 indicated no feeling of moisture on the skin.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=244 dressings
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Patient Assessment Scale: Moisture
8.5 score on a scale
Standard Deviation 2.8

SECONDARY outcome

Timeframe: Baseline through end of treatment, up to 28 days (±3 days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Patient assessment scale completed from baseline visit through end of treatment visits, up to 28 Day (±3 days), using the participant response for each criteria to provide an overall score. Scores ranged from 0 to 10 with 0 indicating a worse outcome and 10 indicating the best outcome. Odour was determined based on the response to "How have you found your experience in terms of odour?" where 0 indicated unacceptable level of odour and 10 indicated no odour.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=244 dressings
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Patient Assessment Scale: Odour
8.8 score on a scale
Standard Deviation 2.5

SECONDARY outcome

Timeframe: Baseline through end of treatment, up to 28 days (±3 days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Patient assessment scale completed from baseline visit through end of treatment visits, up to 28 Day (±3 days), using the participant response for each criteria to provide an overall score. Scores ranged from 0 to 10 with 0 indicating a worse outcome and 10 indicating the best outcome. Exudate was determined based on the response to "How have you found your experience in terms of visible exudate?" where 0 indicated unacceptable level of visible exudate and 10 indicated no visible exudate.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=243 dressings
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Patient Assessment Scale: Exudate
6.5 score on a scale
Standard Deviation 3.0

SECONDARY outcome

Timeframe: Baseline through end of treatment, up to 28 days (±3 days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Patient assessment scale completed from baseline visit through end of treatment visits, up to 28 Day (±3 days), using the participant response for each criteria to provide an overall score. Scores ranged from 0 to 10 with 0 indicating a worse outcome and 10 indicating the best outcome. Protection was determined based on the response to "How protected did the dressing make your wound feel?" where 0 indicated unacceptable level of protection and 10 indicated very protected.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=244 dressings
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Patient Assessment Scale: Protection
8.7 score on a scale
Standard Deviation 2.0

SECONDARY outcome

Timeframe: Baseline through end of treatment, up to 28 days (±3 days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Patient assessment scale completed from baseline visit through end of treatment visits, up to 28 Day (±3 days), using the participant response for each criteria to provide an overall score. Scores ranged from 0 to 10 with 0 indicating a worse outcome and 10 indicating the best outcome. Comfort was determined based on the response to "How have you found your experience in terms of dressing comfort?" where 0 indicated unacceptable level of comfort and 10 indicated very comfortable.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=39 dressings
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Patient Assessment Scale: Comfort
8.9 score on a scale
Standard Deviation 1.7

SECONDARY outcome

Timeframe: Baseline through end of treatment, up to 28 days (±3 days)

Population: All participants enrolled in the study that completed at least one post-baseline assessment for the specified outcome with available data at the time frame indicated.

Patient assessment scale completed from baseline visit through end of treatment visits, up to 28 Day (±3 days), using the participant response for each criteria to provide an overall score. Scores ranged from 0 to 10 with 0 indicating a worse outcome and 10 indicating the best outcome. Comfort was determined based on the response to "How have you found your experience in terms of being able to maintain a normal showering routine? (NA if patient does not have a normal showering routine)" where 0 indicated unacceptable level of impact (unable to bathe) and 10 indicated no negative impact.

Outcome measures

Outcome measures
Measure
ALLEVYN Gentle Border
n=214 dressings
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Patient Assessment Scale: Showering
7.8 score on a scale
Standard Deviation 3.0

Adverse Events

ALLEVYN Gentle Border

Serious events: 4 serious events
Other events: 10 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
ALLEVYN Gentle Border
n=40 participants at risk
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Injury, poisoning and procedural complications
Wound complication
2.5%
1/40 • Number of events 1 • Following dressing application to study completion, up to 28 days.
Adverse events were collected for all participants enrolled in the study that received at least one study treatment (i.e., an application of ALLEVYN Gentle Border dressing).
Respiratory, thoracic and mediastinal disorders
Pulmonary Oedema
2.5%
1/40 • Number of events 1 • Following dressing application to study completion, up to 28 days.
Adverse events were collected for all participants enrolled in the study that received at least one study treatment (i.e., an application of ALLEVYN Gentle Border dressing).
Infections and infestations
Urinary tract infection
2.5%
1/40 • Number of events 1 • Following dressing application to study completion, up to 28 days.
Adverse events were collected for all participants enrolled in the study that received at least one study treatment (i.e., an application of ALLEVYN Gentle Border dressing).
Vascular disorders
Deep vein thrombosis
2.5%
1/40 • Number of events 1 • Following dressing application to study completion, up to 28 days.
Adverse events were collected for all participants enrolled in the study that received at least one study treatment (i.e., an application of ALLEVYN Gentle Border dressing).

Other adverse events

Other adverse events
Measure
ALLEVYN Gentle Border
n=40 participants at risk
ALLEVYN Gentle border is a triple layer foam dressing consisting of a highly absorbent hydrocellular foam pad held between a perforated wound contact layer (WCL), which is coated with a soft silicone gel adhesive and a highly permeable outer top film.
Infections and infestations
Wound infection
7.5%
3/40 • Number of events 3 • Following dressing application to study completion, up to 28 days.
Adverse events were collected for all participants enrolled in the study that received at least one study treatment (i.e., an application of ALLEVYN Gentle Border dressing).
Musculoskeletal and connective tissue disorders
Periarthritis
2.5%
1/40 • Number of events 1 • Following dressing application to study completion, up to 28 days.
Adverse events were collected for all participants enrolled in the study that received at least one study treatment (i.e., an application of ALLEVYN Gentle Border dressing).
Infections and infestations
Infection
2.5%
1/40 • Number of events 1 • Following dressing application to study completion, up to 28 days.
Adverse events were collected for all participants enrolled in the study that received at least one study treatment (i.e., an application of ALLEVYN Gentle Border dressing).
Skin and subcutaneous tissue disorders
Dermatitis
2.5%
1/40 • Number of events 1 • Following dressing application to study completion, up to 28 days.
Adverse events were collected for all participants enrolled in the study that received at least one study treatment (i.e., an application of ALLEVYN Gentle Border dressing).
Injury, poisoning and procedural complications
Wound complication
2.5%
1/40 • Number of events 1 • Following dressing application to study completion, up to 28 days.
Adverse events were collected for all participants enrolled in the study that received at least one study treatment (i.e., an application of ALLEVYN Gentle Border dressing).
Skin and subcutaneous tissue disorders
Skin maceration
2.5%
1/40 • Number of events 1 • Following dressing application to study completion, up to 28 days.
Adverse events were collected for all participants enrolled in the study that received at least one study treatment (i.e., an application of ALLEVYN Gentle Border dressing).
General disorders
Medical device site erosion
2.5%
1/40 • Number of events 1 • Following dressing application to study completion, up to 28 days.
Adverse events were collected for all participants enrolled in the study that received at least one study treatment (i.e., an application of ALLEVYN Gentle Border dressing).
Renal and urinary disorders
Urinary retention
2.5%
1/40 • Number of events 1 • Following dressing application to study completion, up to 28 days.
Adverse events were collected for all participants enrolled in the study that received at least one study treatment (i.e., an application of ALLEVYN Gentle Border dressing).
Infections and infestations
Cellulitis
2.5%
1/40 • Number of events 1 • Following dressing application to study completion, up to 28 days.
Adverse events were collected for all participants enrolled in the study that received at least one study treatment (i.e., an application of ALLEVYN Gentle Border dressing).

Additional Information

Clinical Study Manager

Smith and Nephew

Phone: 1482673917

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: LTE60